Aequitas Research

Hong Jie Seow

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

Independent Insight Provider

IPOs and Placements coverage across Asia Pacific

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Molbio Diagnostics Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/molbio-diagnostics-limited" target="_blank" data-smartkarma-citation="entities:45720:1" rel="noopener">Molbio Diagnostics Limited (1788863D IN)</a> is looking to raise US$229m in its upcoming India IPO.</li>
<li>Molbio Diagnostics is a healthcare technology company specializing in point-of-care molecular diagnostics. Its flagship product, Truenat, is a portable, battery-operated PCR testing system used for the rapid detection of infection.</li>
<li>In this note, we look at the company’s past performance.</li>
</ul>



Molbio Diagnostics Limited (1788863D IN) is looking to raise US$229m in its upcoming India IPO.
Molbio Diagnostics is a healthcare technology company specializing in point-of-care molecular diagnostics. Its flagship product, Truenat, is a portable, battery-operated PCR testing system used for the rapid detection of infection.
In this note, we look at the company’s past performance.


Molbio Diagnostics Limited Pre-IPO: Steady Growths in Topline And Profitability